Elixirgen Therapeutics

About:

Elixirgen Therapeutics is a biotechnology company that specializes in the development of therapies for genetic diseases and vaccines.

Website: https://ElixirgenTx.com

Twitter/X: ElixirgenTx

Top Investors: UTEC - The University of Tokyo Edge Capital Partners

Description:

Elixirgen Therapeutics is a biotechnology company focused on curing humanity’s ailments through stem cell biology. The company concentrates on regenerative and rejuvenative medicine and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent company, Elixirgen, LLC, which has been in active operation since the beginning of 2012.

Total Funding Amount:

$25.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Baltimore, Maryland, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)ElixirgenTherapeutics.com

Founders:

Akihiro Ko, Minoru Ko

Number of Employees:

11-50

Last Funding Date:

2023-11-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai